You are here: Home » International » News » Others
Business Standard

Daewoong Pharma gets approval for Phase 1 trials of coronavirus drug

The company confirmed the safety of the drug in its latest study in partnership with New Delhi-based Mankind Pharma Ltd, Daewoong said in a statement

Topics
Coronavirus Vaccine | South Korea

Reuters  |  SEOUL 

Coronavirus, vaccine, covid
Representative image

By Sangmi Cha

SEOUL (Reuters) - South Korean drugmaker Daewoong Pharmaceutical Co Ltd said on Monday that it had received regulatory approval for Phase 1 clinical trials of its anti-parasitic niclosamide drug to treat COVID-19 patients.

The approval comes after the company in August received Indian regulatory approval to test the drug in Phase 1 trials.

The company confirmed the safety of the drug in its latest study in partnership with New Delhi-based Mankind Pharma Ltd, Daewoong said in a statement.

In September, Daewoong separately launched another overseas human trial of the drug in the Philippians.

Daewoong plans to seek conditional approval for its anti-viral drug, DWRX2003, for emergency use after securing the results from a second-stage clinical study, the company said.

Daewoong had said its anti-viral drug had completely eliminated the novel coronavirus from animals' lungs during pre-clinical testing.

 

 

(Reporting by Sangmi Cha; Editing by Stephen Coates)

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, October 12 2020. 12:59 IST
RECOMMENDED FOR YOU
.